Pfizer will report its Q3 2026 earnings on Nov 3, with investors watching if growth in obesity treatments and other new products can offset declines in COVID-related sales. The company has seen a 25% stock rise this year, driven by strong performance in drugs like Eliquis and Padcev, despite a sharp drop in COVID drug sales. Pfizer aims to sustain growth through new obesity drugs and cancer treatments, with key data expected soon. The report will also reveal progress on cost savings and margin improvements as Pfizer prepares for patent expirations through 2028.
As Pfizer prepares to announce its Q3 earnings on November 3, investors on Pluang show strong interest in the stock, with 85% of order activity on the buy side. On Pluang, Pfizer shares trade at USD 29.78, up 1.12% as of October 29, 2026, 16:21 WIB, nearing its 52-week high of USD 30.42. The stock's dividend yield stands at 5.77%, reflecting ongoing investor confidence amid the company's strategic shifts.
